Abergel's BioActinide Research group conducts a variety of different experiments in the field of coordination chemistry, analytical chemistry, photophysics, biological chemistry, health physics, pharmacology, molecular biology, and cell biology. More specifically, her recent interests have focused on the coordination behavior of lanthanides and actinides. Her group is especially active in developing therapeutics to treat people who have been exposed to radionuclides or atoms that contain excess nuclear charge. These radionuclides can include plutonium, americium, curium, uranium, plutonium, and neptunium. Recent work by the BioActinide Research group has involved synthesis of different actinide chelating agents that could be used to selectively bind radionuclides in the human body in order to safely remove them. Currently, the only drug approved by the Food and Drug Administration to treat radionuclide contamination is diethylenetriaminepentaacetic acid . DTPA has shown some promise is treating plutonium poisoning, but this treatment is specific only to plutonium. Furthermore, DTPA must be administered intravenously, which is an issue due to the extremely time-sensitive nature of radiation poisoning. In the quest of finding a more versatile and easily administered treatment for radiation poisoning, Abergel sees potential in developing new classes of therapeutics. The agent under investigation is an octadentate ligand consisting of four cross-linked dipicolinic acid moieties. This molecule is unique in having the potential for oral consumption in humans. It would function by coordinating as a chelating ligand with toxic actinides in the body before they can cause significant damage. In theory, once the chelating ligands have bound to the actinides, the heavy metal complexes can exit the body naturally by urination. The chelator of interest exhibits higher affinity for lanthanides in vivo than DTPA due to its octadentate structure, and thus it has shown greater efficacy in radionuclide decorporation in living systems. The ligand has shown favorable selectivity for plutonium, americium, uranium, and neptunium decorporation, which is also an improvement over the currently accepted DTPA. Finally, in a separate study, Abergel evaluated the purity of this molecule for potential drug applications, ultimately bringing this effort closer to the development of a deployable treatment solution. An additional research project by Abergel's group involved testing the effectiveness of other analogs containing dipicolinic acid in eliminating plutonium. Results showed that both of the compounds were successful in removing plutonium over a seven-day period in mice. Overall, this work, along with further studies focusing on lanthanide and actinide chelation, has important implications for medicinal and environmental chemistry.
